Current Prescription Status of Contraindicated Drug Combinations Causing Serotonin Syndrome: Analysis of HIRA-NPS Data

키워드

참고문헌 (40)

1. Sternbach H, "The serotonin syndrome", Am J Psychiatry, 148, pp.705~713 (1991)
2. Boyer EW, "The serotonin syndrome", N Engl J Med, 352, pp.1112~1120 (2005)
3. Asch DA, "The Libby Zion Case", N Engl J Med, 318, pp.771~775 (1988)
4. Gill M, "Serotonin syndrome in a child after a single dose of fluvoxamine", Ann Emerg Med, 33, pp.457~459 (1999)
5. Parrott A, "Recreational Ecstasy", MDMA, the serotonin syndrome, and serotonergic neurotoxicity, 2002, pp.71, 837~844
6. Lee DO, "Serotonin syndrome in a child associated with erythromycin and sertraline", Pharmacotherapy, 19, pp.894~896 (1999)
7. Gardner DM, "Sumatriptan contraindications and the serotonin syndrome", Ann Pharmacother, 32, pp.33~38 (1998)
8. Giese SY, "Serotonin syndrome : potential consequences of Meridia combined with Demerol or fentanyl", Plast Reconstr Surg, 107, pp.293~294 (2001)
9. DeSilva KE, "Serotonin syndrome in HIV-infected individuals receiving antiretroviral therapy and fluoxetine", AIDS, 15, pp.1281~1285 (2001)
10. Callaway JC, "Ayahuasca preparations and serotonin reuptake inhibitors : a potential combination for severe adverse interactions", J Psychoactive Drugs, 30, pp.367~369 (1998)
11. Izzo AA, "Interactions between herbal medicines and prescribed drugs", Drugs, 61, pp.2163~2175 (2001)
12. Lange-Asschenfeldt C, "Serotonin syndrome as a result of fluoxetine in a patient with tramadol abuse : plasma level-correlated symptomatology", J Clin Psychopharmacol, 22, pp.440~441 (2002)
13. Turkel SB, "Possible serotonin syndrome in association with 5-HT3 antagonist agents", Psychosomatics, 42, pp.258~260 (2001)
14. Mason PJ, "Serotonin syndrome. Presentation of 2 cases and review of the literature", Medicine (Baltimore), 79, pp.201~209 (2000)
15. Mackay FJ, "Antidepressants and the serotonin syndrome in general practice", Br J Gen Pract, 49, pp.871~874 (1999)
16. Werneke U, "Serotonin syndrome : A clinical review of current controversies", J Integr Neurosci, 19, pp.719~727 (2020)
17. Nguyen CT, "Epidemiology and Economic Burden of Serotonin Syndrome With Concomitant Use of Serotonergic Agents : A Retrospective Study Utilizing Two Large US Claims Databases", Prim Care Companion CNS Disord (2017)
18. 최남경, "한국형 DUR의 효과적 추진전략", 대한의사협회지, 53(12), pp.1130~1138 (2010), 대한의사협회
19. 장철, "New Alert Override Codes for the Drug Utilization Review System Derived from Outpatient Prescription Data from a Tertiary Teaching Hospital in Korea", Healthcare Informatics Research, 22(1), pp.39~45 (2016), 대한의료정보학회[DOI]
20. Kim DS, "Effect of nationwide concurrent drug utilization review program on drug-drug interactions and related health outcome", Int J Qual Health Care (2021)
21. 조여향, "Drug Utilization Review 시행 전후 3차 의료기관에서의 노인주의약품 외래처방 현황 분석", 한국임상약학회지, 29(1), pp.25~32 (2019), 한국임상약학회[DOI]
22. 박혜영, "우리나라의 다제약제 현황과 적정관리 방안에 대한 고찰", 한국임상약학회지, 28(1), pp.1~9 (2018), 한국임상약학회[DOI]
23. Joon Sul Choi, "Serotonin Syndrome following Duloxetine Administration in a Fibromyalgia Patient: Case Report and Literature Review", 대한류마티스학회지, 23(5), pp.332~335 (2016), 대한류마티스학회
24. Meltem Çobanoğulları Direk, "Serotonin Syndrome after Clomipramine Overdose in a Child", Clinical Psychopharmacology and Neuroscience, 14(4), pp.388~390 (2016), 대한정신약물학회
25. 조수현, "Famotidine-induced reversal of meperidine-related serotonin syndrome -a case report-", Korean Journal of Anesthesiology, 70(2), pp.221~223 (2017), 대한마취통증의학회
26. 김록영, "입원 환자 표본 개발에 관한 연구: 국민건강보험 청구자료를 중심으로", 보건행정학회지, 23(2), pp.152~161 (2013), 한국보건행정학회
27. Kim L, "A guide for the utilization of Health Insurance Review and Assessment Service National Patient Samples", Epidemiol Health, 36, pp.e2014008~ (2014)
28. Ahlskog JE, "Rasagiline, Parkinson neuroprotection, and delayed-start trials: still no satisfaction?", Neurology, 74, pp.1143~1148 (2010)
29. McCormack PL, "Rasagiline : a review of its use in the treatment of idiopathic Parkinson’s disease", CNS drugs, 28, pp.1083~1097 (2014)
30. Kakkar AK, "Management of Parkinson’s disease : Current and future pharmacotherapy", Eur J Pharmacol, 750, pp.74~81 (2015)
31. Chen JJ, "Pharmacotherapy for Parkinson’s disease", Pharmacotherapy, 27, pp.161~ (2007)
32. Wong SL, "Parkinson’s disease:Prevalence, diagnosis and impact" (2014), Statistics Canada Ottawa
33. Tanner CM, "Parkinson disease in twins : an etiologic study", JAMA, 281, pp.341~346 (1999)
34. Alves G, "Incidence of Parkinson’s disease in Norway : the Norwegian ParkWest study", J Neurol Neurosurg Psychiatry, 80, pp.851~857 (2009)
35. Grond S, "Clinical pharmacology of tramadol", Clin Pharmacokinet, 43, pp.879~923 (2004)
36. Kim K, "Explosive Increase in Tramadol Use in Korea 2003-2013 : Analysis of Patient Trends Based on the Korea National Health Insurance Database", J Psychoactive Drugs, 52, pp.153~161 (2020)
37. Frank C, "Recognition and treatment of serotonin syndrome", Can Fam Physician, 54, pp.988~992 (2008)
38. Schmidt AW, "Ziprasidone : a novel antipsychotic agent with a unique human receptor binding profile", Eur J Pharmacol, 425, pp.197~201 (2001)
39. Lin PY, "Serotonin syndrome caused by ziprasidone alone", Psychiatry Clin Neurosci, 64, pp.338~339 (2010)
40. Racz R, "Association Between Serotonin Syndrome and Second-Generation Antipsychotics via Pharmacological Target-Adverse Event Analysis", Clin Transl Sci, 11, pp.322~329 (2018)

관련 논문AI추천